Clinical issues in inhibitors

J. Astermark, E. Santagostino, W. Keith Hoots

Research output: Contribution to journalArticle

Abstract

Anamestic inhibitors represent the major complication of haemophilia therapy now that clotting factor concentrates are virtually free of pathogen-transmission risk. Conventional clotting factor replacement is usually insufficient to prevent or treat bleeding in a haemophilia patient with a high responding inhibitor so that alternative treatment with bypassing agents is required. Despite their relative efficacy, their use does not achieve the same invariable haemostasis that patients without inhibitors do following treatment with factor concentrate replacement. This has led to the attempt to eradicate such inhibitors with immune tolerance induction. Success is not invariable, however, and many patients with long-term persistent high-titre inhibitors continue to experience great morbidity. Recently, this has given rise on a limited basis to attempts to use bypassing agents in prophylaxis regimens in an effort to alleviate this extreme morbidity. Each of these strategies is discussed in the context of their relative benefits and risks.

Original languageEnglish
Pages (from-to)54-60
Number of pages7
JournalHaemophilia
Volume16
Issue numberSUPPL. 5
DOIs
Publication statusPublished - Jul 2010

Fingerprint

Blood Coagulation Factors
Hemophilia A
Morbidity
Immune Tolerance
Infectious Disease Transmission
Hemostasis
Therapeutics
Hemorrhage

Keywords

  • Factor VIII bypassing activity
  • Factor VIII inhibitors
  • Haemophilia A
  • Immune tolerance induction

ASJC Scopus subject areas

  • Genetics(clinical)
  • Hematology

Cite this

Clinical issues in inhibitors. / Astermark, J.; Santagostino, E.; Keith Hoots, W.

In: Haemophilia, Vol. 16, No. SUPPL. 5, 07.2010, p. 54-60.

Research output: Contribution to journalArticle

Astermark, J, Santagostino, E & Keith Hoots, W 2010, 'Clinical issues in inhibitors', Haemophilia, vol. 16, no. SUPPL. 5, pp. 54-60. https://doi.org/10.1111/j.1365-2516.2010.02294.x
Astermark, J. ; Santagostino, E. ; Keith Hoots, W. / Clinical issues in inhibitors. In: Haemophilia. 2010 ; Vol. 16, No. SUPPL. 5. pp. 54-60.
@article{f067ae767b84481282d66ae0e61e84d9,
title = "Clinical issues in inhibitors",
abstract = "Anamestic inhibitors represent the major complication of haemophilia therapy now that clotting factor concentrates are virtually free of pathogen-transmission risk. Conventional clotting factor replacement is usually insufficient to prevent or treat bleeding in a haemophilia patient with a high responding inhibitor so that alternative treatment with bypassing agents is required. Despite their relative efficacy, their use does not achieve the same invariable haemostasis that patients without inhibitors do following treatment with factor concentrate replacement. This has led to the attempt to eradicate such inhibitors with immune tolerance induction. Success is not invariable, however, and many patients with long-term persistent high-titre inhibitors continue to experience great morbidity. Recently, this has given rise on a limited basis to attempts to use bypassing agents in prophylaxis regimens in an effort to alleviate this extreme morbidity. Each of these strategies is discussed in the context of their relative benefits and risks.",
keywords = "Factor VIII bypassing activity, Factor VIII inhibitors, Haemophilia A, Immune tolerance induction",
author = "J. Astermark and E. Santagostino and {Keith Hoots}, W.",
year = "2010",
month = "7",
doi = "10.1111/j.1365-2516.2010.02294.x",
language = "English",
volume = "16",
pages = "54--60",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "SUPPL. 5",

}

TY - JOUR

T1 - Clinical issues in inhibitors

AU - Astermark, J.

AU - Santagostino, E.

AU - Keith Hoots, W.

PY - 2010/7

Y1 - 2010/7

N2 - Anamestic inhibitors represent the major complication of haemophilia therapy now that clotting factor concentrates are virtually free of pathogen-transmission risk. Conventional clotting factor replacement is usually insufficient to prevent or treat bleeding in a haemophilia patient with a high responding inhibitor so that alternative treatment with bypassing agents is required. Despite their relative efficacy, their use does not achieve the same invariable haemostasis that patients without inhibitors do following treatment with factor concentrate replacement. This has led to the attempt to eradicate such inhibitors with immune tolerance induction. Success is not invariable, however, and many patients with long-term persistent high-titre inhibitors continue to experience great morbidity. Recently, this has given rise on a limited basis to attempts to use bypassing agents in prophylaxis regimens in an effort to alleviate this extreme morbidity. Each of these strategies is discussed in the context of their relative benefits and risks.

AB - Anamestic inhibitors represent the major complication of haemophilia therapy now that clotting factor concentrates are virtually free of pathogen-transmission risk. Conventional clotting factor replacement is usually insufficient to prevent or treat bleeding in a haemophilia patient with a high responding inhibitor so that alternative treatment with bypassing agents is required. Despite their relative efficacy, their use does not achieve the same invariable haemostasis that patients without inhibitors do following treatment with factor concentrate replacement. This has led to the attempt to eradicate such inhibitors with immune tolerance induction. Success is not invariable, however, and many patients with long-term persistent high-titre inhibitors continue to experience great morbidity. Recently, this has given rise on a limited basis to attempts to use bypassing agents in prophylaxis regimens in an effort to alleviate this extreme morbidity. Each of these strategies is discussed in the context of their relative benefits and risks.

KW - Factor VIII bypassing activity

KW - Factor VIII inhibitors

KW - Haemophilia A

KW - Immune tolerance induction

UR - http://www.scopus.com/inward/record.url?scp=77955026316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955026316&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2516.2010.02294.x

DO - 10.1111/j.1365-2516.2010.02294.x

M3 - Article

C2 - 20590857

AN - SCOPUS:77955026316

VL - 16

SP - 54

EP - 60

JO - Haemophilia

JF - Haemophilia

SN - 1351-8216

IS - SUPPL. 5

ER -